Trials / Recruiting
RecruitingNCT06360601
Intravenous Labetalol Versus Hydralazine in Preeclampsia
The Effect of Intravenous Infusion of Labetalol Versus Hydralazine on Cerebral Hemodynamics of Preeclampsia Patients Prospective Randamized Study
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Tanta University · Academic / Other
- Sex
- Female
- Age
- 25 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
We study the effect of intravenous labetalol versus hydralazine in sever preeclampsia patients on cerebral blood flow and neurological outcome
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Labetalol Injection | Labetalol intravenous infusion 20ml/hr |
| DRUG | HydrALAZINE Injection | Hydralazine intravenous infusion 5mg/hr |
Timeline
- Start date
- 2024-04-01
- Primary completion
- 2024-11-20
- Completion
- 2024-12-20
- First posted
- 2024-04-11
- Last updated
- 2024-12-02
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06360601. Inclusion in this directory is not an endorsement.